CELL DISCOV 润色咨询

Cell Discovery

出版年份：暂无数据 年文章数：199 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：0.7% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    昨天 左岸的回忆 来自山东省

    cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2023-06-06 尊严

    Cell Discovery能比得上Mol Cell不？

    7

    展开7条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2023-05-15 ms5000000882465531 来自广东省

    Manuscript Under Consideration已经两个月了，请问是送审了吗？

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-05-20 dgdgdgygygyg

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2019-04-29 05482

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2019-09-15 加州理工的工人

    今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-04-25 dgdgdgygygyg

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。

    8

    展开8条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2018-09-03 ms4591412325009157

    这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-11-03 ms5000001380422750

    投稿11天，不知道送审没

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2160625, encodeId=cfc32160625c8, content=cell discovery 最新纯生信https://www.nature.com/articles/s41421-023-00591-7, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/23/e88f56a102bd9696233dc1d5ea737882.jpg, createdBy=03485321215, createdName=左岸的回忆, createdTime=Mon Oct 02 13:35:48 CST 2023, time=昨天, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141041, encodeId=5ca4214104108, content=Cell Discovery能比得上Mol Cell不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Tue Jun 06 10:38:36 CST 2023, time=2023-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2134511, encodeId=5b3d2134511d4, content=Manuscript Under Consideration已经两个月了，请问是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3475520673, createdName=ms5000000882465531, createdTime=Mon May 15 15:30:16 CST 2023, time=2023-05-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1221088, encodeId=d08412210887e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：nature旗下的杂志通讯邮箱（投稿用的通讯邮箱）绑定research square，可以看到极其详细的投稿状态。包括邀请了几个审稿人，几个审稿人同意，几个审稿人返回意见等等，你们都不知道吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Fri May 20 06:17:17 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-05-24 ms7000000308199462

    请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？

    1

    展开1条回复
共141条页码: 1/15页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分